Although the clinical significance of low IGF1 concentrations in patients with T1DM remains unclear at present, CIPII could have an additional benefit on top of glycaemic control by altering the dysregulated GH–IGF system by increasing portal insulin concentrations. This evidence concerns the gene INS and type 1 diabetes mellitus.